Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PDGFRB rearrange |
| Therapy | Imatinib |
| Indication/Tumor Type | myelodysplastic/myeloproliferative neoplasm |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PDGFRB rearrange | myelodysplastic/myeloproliferative neoplasm | sensitive | Imatinib | FDA approved - On Companion Diagnostic | Actionable | Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFRB rearrangements and detected by a companion diagnostic (FDA.gov). | detail... detail... detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| FDA.gov | Full reference... | |
| Full reference... | ||
| Gleevec (imatinib) FDA Drug Label | Full reference... |